One of the critical challenges well known in the field is the limitation of the patient tissue biopsy for establishing an ibrutinib-resistant ABC DLBCL with MYD88 and CD79A and B mutations. The gene discussed is CD79A; the disease is diffuse large B-cell lymphoma.